Please Wait...

  • +91 22 2783 1455

  • Product background
    LAVIXABAN 2.5 (Apixaban Tablets 2.5mg)

WARNING: CAUTION : PLEASE NOTE :
The content or product detailing is not intended to replace advice from your prescribing doctor or healthcare professional. Lavina Pharma is not responsible for such actions by consumers. For any further information about the product please contact +91 22 2783 1455 and we can provide you the details.

LAVIXABAN is indicated to reduce the risk of stroke and systemic embolism in patients with nonvalvular atrial fibrillation.

Prophylaxis of deep vein thrombosis hip or knee replacement surgery.

LAVIXABAN 2.5 is a prescription medication containing 2.5 mg of apixaban, an oral anticoagulant. It is used to reduce the risk of stroke and blood clots in patients with atrial fibrillation and to

treat or prevent deep vein thrombosis (DVT) and pulmonary embolism (PE). Apixaban works by inhibiting Factor Xa, a key enzyme in the blood coagulation process.

The tablet is easy to administer and is typically taken twice daily, with or without food. Regular monitoring is not required, making it a convenient option for patients managing anticoagulation therapy.


COMPOSITION

Each film coated tablet contains:

Apixaban IH …………..2.5 mg

Excipients……………...  Q.S

 Oral 

DOSAGE

 As directed by the physician.

SIDE EFFECT

•    Increased risk of Thrombotic events after premature discontinuation

•    Bleeding

•   Spinal/Epidural Anesthesia or Puncture





PRECAUTION

        Premature discontinuation of any oral anticoagulant, including LAVIXABAN, in the absence of    

        adequate alternative anticoagulation increases the risk of thrombotic events. An increased rate

        of stroke was observed during the transition from LAVIXABAN to warfarin in clinical trials in atrial

        fibrillation patients. If LAVIXABAN is discontinued for a reason other than pathological bleeding

        or completion of a course of therapy, consider coverage with another anticoagulant.

 

Concomitant use of drugs affecting hemostasis increases the risk of bleeding. These include

aspirin and other antiplatelet agents, other anticoagulants, heparin, thrombolytic agents, selective

serotonin reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, and nonsteroidal anti-

inflammatory drugs (NSAIDs)

Advise patients of signs and symptoms of blood loss and to report them immediately or go to an

emergency room. Discontinue LAVIXABAN in patients with active pathological hemorrhage.

 

       Direct-acting oral anticoagulants (DOACs), including LAVIXABAN, are not recommended for use 

        in patients with triple-positive antiphospholipid syndrome (APS). For patients with APS (especially

       those who are triple positive [positive for lupus anticoagulant, anticardiolipin, and anti–beta 2-

       glycoprotein I antibodies]), treatment with DOACs has been associated with increased rates of

       recurrent thrombotic events compared with vitamin K antagonist therapy.





PRESENTATION

6 x 10 Tablets